Pembrolizumab on pre-existing inclusion body myositis: a case report.

Naohiro UchioAtsushi UnumaToshiyuki KakumotoMasao OsakiYoshitaka ZenkeKenichi SakutaAkatsuki KubotaYoshikazu UesakaTatsushi TodaJun Shimizu

Published in: BMC rheumatology (2020)

In patients with slowly progressive limb weakness, sIBM should be explored before ICI therapy. In addition, if patients show high CK levels after ICI introduction, it is necessary to confirm whether they have sIBM in order to avoid unnecessary immunosuppressive therapies and assess whether they can tolerate ICI reintroduction.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
multiple sclerosis
peritoneal dialysis
patient reported outcomes
mesenchymal stem cells
bone marrow
smoking cessation